Would the recent use of high dose glucocorticoids impact your selection of first-line therapy for patients with intermediate-poor risk metastatic RCC?   

Definitely a common clinical scenario, unfortunately. Such patients often have poor risk highly symptomatic disease. In such symptomatic patients, we tend to prefer a VEGF/TKI-based regimen as first line therapy considering the relatively lower rate of primary progressive disease, higher objective r...